{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-227921","form_type":"8-K","ticker":"TCRT","cik":"0001107421","company_name":"Alaunos Therapeutics, Inc.","filed_at":"2026-05-18T12:00:43+00:00","discovered_at":"2026-05-18T12:05:00.408748+00:00","generated_at":"2026-05-18T12:07:56.332422+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Alaunos announces preclinical ALN1003 data; cash only $0.354M, runway into Q2 2026","bullets":["ALN1003 showed significantly lower HOMA-IR (p=0.0006) and higher adiponectin-to-leptin ratio in DIO mouse models.","Blinded liver histology: ALN1003-treated mice had mean NAS scores of 2.7 and 1.3 vs control score of 5.","Data are from non-GLP studies with small sample sizes; no human trials conducted yet.","Cash and equivalents $0.354M as of March 31, 2026; company seeking additional financing.","Plans to advance ALN1003 with further preclinical dose optimization and metabolic phenotyping."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-227921","json":"https://secwatch.observer/filing/0001193125-26-227921.json","markdown":"https://secwatch.observer/filing/0001193125-26-227921.md","text":"https://secwatch.observer/filing/0001193125-26-227921.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1107421/000119312526227921/0001193125-26-227921-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1107421/000119312526227921/tcrt-20260302.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T12:07:56.332422+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}